Why isn t weight a factor in adjusting nivolumab dose?

What is the rationale behind not adjusting nivolumab doses based on weight?

Nivolumab, a monoclonal antibody used to treat various types of cancer, has a similar dose across different body weights, which might not align with the conventional practice of dose adjustment based on a patient's body weight. The Food and Drug Administration (FDA) approval for nivolumab states that the recommended dose for adults is 3 mg/kg administered as an intravenous infusion over 30 minutes every 2 weeks [1].

Why was weight not considered a critical factor in the dosing of nivolumab?

When considering dosing, manufacturers often account for variations in body weight as this can affect the amount of the drug that reaches the tumor site. However, researchers have established the efficacy and safety of nivolumab in diverse populations across clinical trials, which has led them to opt for a fixed dosing approach. [2]

According to clinical trial data and FDA documentation, the efficacy of nivolumab was not found to be associated with body weight. Instead, tumor size, PD-L1 expression, and number of metastatic sites were identified as predictive biomarkers of response. In light of this evidence, the fixed dosing was established to achieve optimal clinical outcomes, and there is limited data suggesting that a weight-adjusted approach is necessary [3].

Is there any ongoing debate or concerns about dose adjustments for nivolumab?

As with many other cancer treatments, further research is crucial to improve the efficacy and safety of nivolumab and to identify potential dosing strategies that could be more tailored to individual patient needs. Some ongoing clinical trials are investigating the effects of different dosing schedules, body weight and performance status, and other clinical and genomic factors to refine nivolumab treatment [4].

References

[1] US FDA approval for nivolumab https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514s000lbledt.pdf

[2] Wolchok JD et al (2016) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 381(14): 1331-1342.

[3] Larkin J et al (2020) First-line nivolumab plus ipilimumab versus ipilimumab in patients with untreated BRAF V600 wild-type advanced melanoma: primary analysis of the CheckMate 067 randomized clinical trial. J Am Acad Dermatol 82(5): 1070-1079

[4] Nivolumab: Drug information and clinical trials for https://drugpatenthawk.com/2020/11/17/nivolumab-anti-cancer-drug-patient